GlassScriptPhysician profile
Trista Kramer
NPI 1578284907
$2,316.86
in general payments reported to CMS, 2019-2025
22 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $759 · 2024: $932 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $332.11 | 2024-2025 | |
| Becton, Dickinson and Company | $304.00 | 2024 | Phasix Mesh |
| Medtronic, INC. | $187.65 | 2023 | Mazor X System, Catalyft Pl Expandable Interbody System, Clydesdale Ptc Spinal System |
| Kerecis Limited | $166.70 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Boston Scientific Corporation | $149.15 | 2023 | |
| Enterra Medical, INC. | $143.93 | 2024 | |
| Baxter Healthcare | $124.00 | 2024 | Perclot |
| Edwards Lifesciences Corporation | $123.22 | 2023 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $122.26 | 2022 | |
| Janssen Scientific Affairs, LLC | $111.29 | 2023 | Stelara |
| Integra Lifesciences Corporation | $105.82 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ucb, INC. | $98.02 | 2023 | Briviact |
| Neurocrine Biosciences, INC. | $89.28 | 2023 | |
| Shionogi INC | $51.63 | 2024-2025 | Fetroja |
| Sanara Medtech INC. | $46.72 | 2024 | Celleraterx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $43.15 | 2025 | Nuzyra |
| Melinta Therapeutics, LLC | $25.54 | 2024 | Orbactiv, Kimyrsa, Vabomere |
| Aimmune Therapeutics, INC. | $24.71 | 2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $20.96 | 2024 | Gattex |
| Merck Sharp & Dohme LLC | $17.17 | 2024 | Dificid, Zerbaxa |
| Vertex Pharmaceuticals Incorporated | $15.14 | 2024 | |
| Evoke Pharma, INC. | $14.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trista Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.